Genome-based assessment of safety characteristics of <i>Lacticaseibacillus paracasei</i> NY1301 and genomic differences in closely related strains marketed as probiotics-Reference-Cited by-同舟云学术

Genome-based assessment of safety characteristics of <i>Lacticaseibacillus paracasei</i> NY1301 and genomic differences in closely related strains marketed as probiotics

Published:2024 Issue:2 Volume:43 Page:145-149
ISSN:2186-3342
Container-title:Bioscience of Microbiota, Food and Health
language:en
Short-container-title:

Author:

FUKAO Masanori¹,OKI Atsushi²,SEGAWA Shuichi¹

Affiliation:

1. Nissin York Co., Ltd., 3-6-11 Higashi-Nihonbashi, Chuo-ku, Tokyo 103-0004, Japan

2. Nissin Foods Holdings Co., Ltd., 2100 Tobuki, Hachioji-shi, Tokyo 192-0001, Japan

Publisher

BMFH Press

Link

https://www.jstage.jst.go.jp/article/bmfh/43/2/43_2023-072/_pdf

Reference23 articles.

1. 1. Sugahara H, Hirota T. 2021. Chapter 3—Probiotic beverages in Japan (some history and current developments). In Probiotic Beverages, Panda SK, Kellershohn J, Russell I (eds), Academic Press, Cambridge, pp. 35–48.

2. 2. Azuma Y, Sato M. 2001. Lactobacillus casei NY1301 increases the adhesion of Lactobacillus gasseri NY0509 to human intestinal caco-2 cells. Biosci Biotechnol Biochem 65: 2326–2329.

3. 3. Azuma Y, Ito K, Ohki A, Inoue A, Inoue K, Sato M, Benno Y. 2001. Effects of a milk drink fermented with Lactobacillus gasseri NY0509 and Lactobacillus casei NY1301 on fecal microflora in healthy volunteers. Nippon Shokuhin Kagaku Kogaku Kaishi 48: 35–43.

4. 4. Nakamura E, Tatsuaki T, Tagawa K, Segawa S, Ueda K, Saito J. 2020. Intake of a Lactobacillus paracasei subsp. paracasei NY1301-containing beverage improves intestinal flora compositions in constipated subjects—a randomized, placebo-controlled, double blind, parallel-group study. Jpn Pharmacol Ther 48: 1793–1803.

5. 5. Segawa S, Tagawa K, Okabe Y, Nagashima H. 2021. Effect of beverage containing Lactobacillus paracasei subsp. paracasei NY1301 on fatigue and quality of sleep—a randomized, double‒blind, placebo‒controlled parallel study. Jpn Pharmacol Ther 49: 2135–2148.